Meeting
2014 ASCO Annual Meeting
Mesothelin expression in thymic epithelial tumors (TETs).
Authors
Yuanbin Chen
National Cancer Institute at the National Institutes of Health, Bethesda, MD
Yuanbin Chen , Anish Thomas , Arlene W Berman , Markku Miettinen , Raffit Hassan , Arun Rajan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Thymic Malignancies
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7607)
DOI
10.1200/jco.2014.32.15_suppl.7607
Abstract #
7607
Poster Bd #
215
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Lenvatinib for the treatment of thymic epithelial tumors (TETs): A real-life multicenter experience.
First Author: Jose Carlos Benitez
Poster
2021 ASCO Annual Meeting
Clinicogenomic characterization of metastatic thymic epithelial tumors.
First Author: Fatemeh Ardeshir-Larijani
Poster
2020 ASCO Virtual Scientific Program
Low-dose oral etoposide is an active option for patients with heavily pre-treated thymic epithelial tumors.
First Author: Margaret Ottaviano
Poster
2018 ASCO Annual Meeting
A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.
First Author: Matteo Perrino